Jian-xing Ma, M.D., Ph.D.
Year 1: 1,382,234.00 Year 2: 1,498,797.00
Nanoparticle-mediated drug delivery for the treatment of Diabetic Retinopathy and Age-Related Macular Degeneration
The company’s first therapeutic target CLT-003 is an injectable formulation to treat Diabetic Macular Edema (DME), a condition for which no FDA approved therapeutic currently exists. The compound utilizes a new mechanism of action and is potentially safer than off-label competitors such as steroid-based therapies, and more potent than anti-VEGFs. Furthermore, the company is currently developing a sustained-release formulation of CLT-003 that will be injected 2 to 3 times a year, a significant improvement over the 4 to 12 injections/year for the most advanced drugs in development. An IND for this drug is expected in the first half of 2010.
Biopharmaceutical research and development company, focused on ocular human therapeutics, and pre-clinical contract research for the pharmaceutical industry.
Founded in 2004, Charlesson is a development-stage ocular pharmaceutical company in Oklahoma City. The company has 20 employees and is located in the 800 Building of the PHF Research Park, which is the center of biomedical research in Oklahoma and surrounding states. Charlesson was founded based on technology developed independently, and at the University of Oklahoma Health Sciences Center (OUHSC). The company is engaged in two primary lines of business: